ProQR Therapeutics N.V. (PRQR) Form 6-K — Oct 28, 2026
ProQR Therapeutics announced it will present clinical and preclinical progress on AX-0810 and AX-0811, its NTCP-targeting Axiomer RNA editing programs for cholestatic disease, at TIDES Europe, AASLD The Liver Meeting 2026, and Nature's RNA at the Bench and Bedside V. AX-0810 Phase 1 data will be featured in two AASLD posters, including a late-breaking poster showing first in-person evidence of in vivo Axiomer RNA editing of NTCP. Previously disclosed findings include a favorable safety and tolerability profile and successful NTCP target engagement.
Key figures
- Aasld liver meeting dates
- November 5-9, 2026
- Tides europe plenary date
- November 3, 2026
- Ax0811 phase1 initial data
- early January 2027
- Nature conference presentation date
- December 9, 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.